FINWIRES · TerminalLIVE
FINWIRES
Eli Lilly and Company

Eli Lilly and Company

$LLY
NYSEHealthcare

198 stories mentioning Eli Lilly and CompanyUpdated 2d ago

Eli Lilly trades amid a proposed permanent CMS Medicare drug price negotiation framework; an executive sold $2.88 million in shares per an SEC filing.

What are analysts saying about Eli Lilly and Company?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on Eli Lilly and Company?

Sectors

Sector Update: Healthcare Stocks Gain Friday Afternoon

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index advancing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.2%.The iShares Biotechnology ETF (IBB) increased 0.2%.In corporate news, Merck (MRK) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Keytruda, in combination with Padcev, to treat a type of bladder cancer. Merck shares jumped 5%.Eli Lilly (LLY) shares rose 2.2% after it said Friday that a new analysis from two phase 3 trials showed that its GLP-1 pill Foundayo at all doses tested was linked to "clinically significant" weight loss in adults 65 years old and older with obesity or overweight.Novo Nordisk's (NVO) Ozempic and Eli Lilly's Mounjaro are being linked to better cancer outcomes in four new studies, The Wall Street Journal reported. The weight-loss and diabetes drugs suggest they could reduce tumor progression, lower overall chance of death, and avert the risk of developing breast cancer, the report said. Novo shares added 1%.

$LLY$MRK$NVO
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding about 0.7%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, West Pharmaceutical Services (WST) shares rose 3.1% after the company said it has restored its core enterprise systems following a recent cybersecurity attack.Eli Lilly (LLY) shares added 2.6% after the company said its investigational retatrutide delivered "clinically meaningful" weight loss in a phase 3 trial, where all doses met the primary and key secondary endpoints at 80 weeks.Hims & Hers Health (HIMS) said Thursday that it has launched generic semaglutide for eligible customers in Canada. Its shares gained 2.7%.Moderna's (MRNA) experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory panel on June 18, Bloomberg reported. Moderna shares were down 1.5%.

$HIMS$LLY$MRNA$WST
Wire

Jefferies Lifts Eli Lilly Price Target to $1,330 From $1,300

Eli Lilly (LLY) has an average rating of buy and mean price target of $1,247.64, according to analysts polled by FactSet.Price: $1038.83, Change: $+19.96, Percent Change: +1.96%

$LLY
Sectors

Sector Update: Healthcare Stocks Rise Thursday Afternoon

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index increasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.5%.The iShares Biotechnology ETF (IBB) was up 0.6%.In corporate news, Eli Lilly (LLY) shares rose 2.1% after the company said its investigational retatrutide delivered "clinically meaningful" weight loss in a phase 3 trial, where all doses met the primary and key secondary endpoints at 80 weeks.Hims & Hers Health (HIMS) said Thursday that it has launched generic semaglutide for eligible customers in Canada. Its shares popped 3.3%.Moderna's (MRNA) experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory panel on June 18, Bloomberg reported. Moderna shares were down 1.5%.

$HIMS$LLY$MRNA
Sectors

Sector Update: Healthcare

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index increasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.5%.The iShares Biotechnology ETF (IBB) was up 0.6%.In corporate news, Eli Lilly (LLY) shares rose 2.3% after it said Thursday its investigational triple hormone receptor agonist retatrutide delivered "clinically meaningful" weight loss in a phase 3 obesity trial, where all doses met the primary and key secondary endpoints at 80 weeks.

$LLY
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each adding 0.4%.The iShares Biotechnology ETF (IBB) was shedding 1.6%.In corporate news, Boston Scientific (BSX) shares jumped 6% after it said Monday that it invested $1.5 billion for an approximately 34% stake in privately held MiRus, gaining an exclusive option to acquire the company's TAVR business. Separately, Boston Scientific entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase (JPM) as part of its $5 billion share buyback authorization.Claritev (CTEV) shares jumped past 19% after the company issued a response to a Thursday media article stating that the Department of Justice has launched a criminal probe into Claritev. The company said Monday it has not been informed by the DOJ that it is the target of an investigation at no point in the subsequent two years after receiving a 2024 subpoena.Eli Lilly (LLY) was among the pharmaceutical firms highlighted in Monday's Supreme Court order list, which included widespread denials of certiorari in drugmaker-related and other commercial cases, according to the Court's May 18 orders. Lilly shares fell 1.7%.Berkshire Hathaway (BRK.A, BRK.B) said Friday in a regulatory filing that it sold all of its stake in UnitedHealth (UNH). UnitedHealth shares were down 0.8%.

$BSX$CTEV$LLY$UNH
Sectors

Sector Update: Healthcare Stocks Advance Monday Afternoon

Healthcare stocks rose Monday afternoon, with the NYSE Healthcare Index adding 0.4% and the State Street Healthcare Select Sector SPDR ETF (XLV) up 0.3%.The iShares Biotechnology ETF (IBB) was shedding 1.5%.In corporate news, Claritev (CTEV) shares jumped 28% after the company issued a response to a Thursday media article stating that the Department of Justice has launched a criminal probe into Claritev. The company said Monday it has not been informed by the DOJ that it is the target of an investigation at no point in the subsequent two years after receiving a 2024 subpoena.Eli Lilly (LLY) was among the pharmaceutical firms highlighted in Monday's Supreme Court order list, which included widespread denials of certiorari in drugmaker-related and other commercial cases, according to the Court's May 18 orders. Lilly shares fell 1.4%.Berkshire Hathaway (BRK.A, BRK.B) said Friday in a regulatory filing that it sold all of its stake in UnitedHealth (UNH). UnitedHealth shares were down 1.4%.

$CTEV$LLY$UNH
Wire

Market Chatter: Dell Added 1,000 AI Factory Customers Last Quarter

Dell Technologies' (DELL) AI Factory added 1,00 customers in the past quarter, bringing the total to 5,000 for its product line of servers used to power artificial intelligence work with Nvidia's (NVDA) chips, software and services, Bloomberg reported Monday, citing an interview with Chief Executive Michael Dell.Eli Lilly (LLY), Honeywell International (HON) and Samsung are among its customers, the report said. Dell had about 4,000 clients when it reported its quarterly results in February.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $239.90, Change: $-2.09, Percent Change: -0.87%

$DELL$HON$LLY$NVDA
Wire

Eli Lilly Among Petitioners Denied Certiorari as Supreme Court Rejects Multiple Appeals

Eli Lilly (LLY) was among the pharmaceutical firms highlighted in Monday's Supreme Court order list, which included widespread denials of certiorari in drugmaker-related and other commercial cases, according to the Court's May 18 orders.The Court vacated and remanded several cases, including voting rights disputes, while rejecting review in multiple pharmaceutical and healthcare-related petitions, reducing the likelihood of near-term Supreme Court intervention in those matters.The Court granted review in one education case while denying dozens of appeals across civil, criminal, regulatory, and healthcare matters, with Justice Sotomayor separately concurring in the denial of certiorari in a sentencing case in which relief had already been granted.Shares of Eli Lilly were down 2.2% in Monday trading.Price: $985.25, Change: $-19.68, Percent Change: -1.96%

$LLY
Sectors

Sector Update: Health Care Stocks Mixed Wednesday Afternoon

Health care stocks were mixed Wednesday afternoon, with the NYSE Health Care Index increasing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.1%.The iShares Biotechnology ETF (IBB) climbed 1.8%.In corporate news, CVS Health (CVS) raised its full-year earnings outlook after reporting better-than-expected Q1 results driven by improvement in its health-care benefits segment. Its shares gained 6.8%.Novo Nordisk (NVO) expects generic versions of its Ozempic medication to face approval delays in China until next year, Bloomberg reported, citing the drugmaker. The patent for semaglutide, the main ingredient in Ozempic and Wegovy, expired in China in March, but the company said it still has regulatory data protection until April 2027 due to a trade agreement between China and Switzerland, Bloomberg reported. Novo shares rose 2.5%.Eli Lilly (LLY) is looking to raise about $8 billion from an investment-grade bond sale to fund an acquisition spree, Bloomberg reported. Lilly shares added 0.3%.

$CVS$LLY$NVO
Wire

Update: Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions

(Updates with the company's response in the fourth paragraph.)Eli Lilly (LLY) is looking to raise about $8 billion from an investment-grade bond sale to fund an acquisition spree, Bloomberg reported Wednesday, citing people with direct knowledge of the matter.The company is offering notes in as many as eight tranches, with maturities ranging from two to 40 years, according to the report.Proceeds will be used for general corporate purposes and potentially fund all or part of the upfront cash consideration and related expenses linked to the Centessa Pharmaceuticals (CNTA) and Kelonia Therapeutics acquisitions, Bloomberg said.An Eli Lilly spokesperson said the company is excited to be in the investment-grade market. Following strong Q1 earnings, an upgrade from S&P to AA- with a positive outlook, and a favorable market backdrop, Lilly is encouraged by investor interest, the spokesperson added.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $992.35, Change: $+3.48, Percent Change: +0.35%

$CNTA$LLY
Wire

Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions

Eli Lilly (LLY) is looking to raise about $8 billion from an investment-grade bond sale to fund an acquisition spree, Bloomberg reported Wednesday, citing people with direct knowledge of the matter.The company is offering notes in as many as eight tranches, with maturities ranging from two to 40 years, according to the report.Proceeds will be used for general corporate purposes and potentially fund all or part of the upfront cash consideration and related expenses linked to the Centessa Pharmaceuticals (CNTA) and Kelonia Therapeutics acquisitions, Bloomberg said.Eli Lilly did not immediately respond to a request for comment by.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $991.81, Change: $+2.94, Percent Change: +0.30%

$CNTA$LLY
Wire

Eli Lilly to Invest Additional $4.5 Billion in Indiana Manufacturing Sites

Eli Lilly (LLY) said Wednesday it will invest an additional $4.5 billion in two of its facilities in Lebanon, Indiana, bringing its total capital expansion commitments in the state to more than $21 billion since 2020.The additional investment will fund new process designs and technologies at Lilly Lebanon Advanced Therapies, a dedicated genetic medicine plant opening Wednesday, and Lilly Lebanon API, an active pharmaceutical ingredient facility expected to open in 2027, the company said.The Lebanon Advanced Therapies site is designed to handle operations ranging from clinical research to commercial production of therapies targeting diseases at the genetic level, Lilly said.The Lebanon campus will also include the planned Lilly Medicine Foundry facility, the company said.Price: $987.86, Change: $-0.61, Percent Change: -0.06%

$LLY
Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Monday afternoon, with the NYSE Health Care Index decreasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.4%.The iShares Biotechnology ETF (IBB) rose 1.6%.In corporate news, Sanofi (SNY) said Monday it will invest 294 million Canadian dollars ($216 million) to expand its global AI Centre of Excellence in Toronto in a bid to accelerate the development and delivery of medicines. Its shares were down past 5%.Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico. Amgen shares were down 2.1%.Eli Lilly (LLY) shares added 0.7% after Barclays lifted the company's price target to $1,400 from $1,350, while keeping its overweight rating.Vanda Pharmaceuticals (VNDA) shares jumped past 7% after it said Monday its motion sickness drug Nereus is now commercially available in the US.

$AMGN$LLY$SNY$VNDA
Sectors

Sector Update: Health Care Stocks Softer in Afternoon Trading

Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.3%.The iShares Biotechnology ETF (IBB) rose 1.3%.In corporate news, Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico. Amgen shares were down 2.1%.Vanda Pharmaceuticals (VNDA) shares jumped past 5% after it said Monday its motion sickness drug Nereus is now commercially available in the US.Eli Lilly (LLY) shares added 0.2% after Barclays lifted the company's price target to $1,400 from $1,350, while keeping its overweight rating.Moderna (MRNA) is showing continued advancement across its pipeline, with progress in cancer vaccines and infectious disease programs supporting a more balanced risk-reward profile, RBC Capital Markets said in a note. RBC maintained its sector perform rating on the stock and raised its price target to $38 from $35. Moderna shares rose 4.6%.

$AMGN$LLY$MRNA$VNDA
Wire

Eli Lilly Keeps Quarterly Dividend at $1.73 a Share, Payable June 10 to Shareholders of Record as of May 15

Eli Lilly Keeps Quarterly Dividend at $1.73 a Share, Payable June 10 to Shareholders of Record as of May 15

$LLY
Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Friday afternoon with the NYSE Health Care Index easing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 0.4%.The iShares Biotechnology ETF (IBB) shed 0.6%.In corporate news, Moderna (MRNA) affirmed its 2026 revenue growth outlook and reported better-than-expected Q1 results amid higher COVID vaccine sales. The stock still declined 1.4%.Amgen's (AMGN) Q1 EPS beat was primarily driven by lower administrative costs and taxes, Morgan Stanley said. Amgen shares fell 4.9%.Eli Lilly's (LLY) international rollout of its new oral weight-loss drug is off to a strong start, with early demand for Foundayo building quickly, BofA Securities said. Lilly shares rose 3.1%.Novo Nordisk (NVO) rebranded its oral semaglutide medication for type 2 diabetes as Ozempic. It was formerly marketed as Rybelsus. Novo shares gained 3.9%.

$AMGN$LLY$MRNA$NVO
Sectors

Sector Update: Health Care

Health care stocks were softer late Friday afternoon with the NYSE Health Care Index fractionally lower and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.4%.The iShares Biotechnology ETF (IBB) shed 0.7%.In corporate news, Eli Lilly's (LLY) international rollout of its new oral weight-loss drug is off to a strong start, with early demand for Foundayo building quickly, BofA Securities said in a report. Lilly shares were up 3%.

$LLY
Wire

Eli Lilly Strong Q1 Results Show Stable Pricing, Foundayo Volatility Remains, RBC Says

Eli Lilly (LLY) reported strong Q1 results driven by GLP-1 drugs, with fundamentals remaining solid and pricing stabilizing, RBC Capital Markets said, while warning that volatility around its new drug Foundayo remains.The company raised its full-year 2026 adjusted EPS outlook to $35.50 to $37 per share from $33.50 to $35 and reported Q1 results above expectations. RBC also lifted its full-year 2026 EPS forecast to $36.24 from $33.59 and increased its revenue estimate to $85.1 billion from $83.2 billion.Foundayo has reached about 20,000 prescriptions so far. The investment firm said it is still too early to assess demand and expects data to remain volatile as the launch develops.The brokerage said it was "encouraging" that Mounjaro prescriptions in India rose about 10% even after the entry of cheaper generics. It also noted that pricing trends have stabilized, with management reaffirming low-to-mid teens year-on-year declines.RBC maintained its outperform rating and $1,250 price target, saying the stock remains undervalued given long-term growth prospects.Price: $962.47, Change: $+27.87, Percent Change: +2.98%

$LLY
Wire

Eli Lilly's Oral Weight-Loss Drug Gains Early Momentum as Prescriptions Surge, BofA Says

Eli Lilly's (LLY) international rollout of its new oral weight-loss drug is off to a strong start, with early demand for Foundayo building quickly, BofA Securities said Thursday in a report.More than 20,000 patients were treated with Foundayo in the first 3.5 weeks, up from 5,000 in the first two weeks, BofA said. Lilly expects access through several major pharmacy benefit managers by mid-May and pointed to Zepbound's 55% share of new-to-brand prescriptions as the closest comparison for how early Foundayo uptake is trending, the report said.International demand for Mounjaro also remains strong, with about 75% of volume tied to chronic weight management rather than type 2 diabetes, the report said.BofA raised its 2026 sales forecast by 8% to $32.5 billion, reflecting continued strength across Lilly's incretin portfolio, and lifted its EPS estimate by 6% to $36.46, in line with updated company guidance.BofA cut its price target on Lilly stock to $1,133 from $1,294 after applying a lower valuation multiple to reflect longer-term pricing uncertainty. Its buy rating was reiterated.Price: $964.51, Change: $+29.91, Percent Change: +3.20%

$LLY

Showing 141-160 of 198

Track with the FINWIRES app suite

FolioX
FolioX
Track Eli Lilly and Company in your portfolio
WheelAI
WheelAI
Analyze Eli Lilly and Company options with the wheel strategy
StockInsider
StockInsider
See market sentiment on Eli Lilly and Company